QI
EGRX

QS Investors’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

QS Investors’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$351K Hold
8,195
– – ﹤0.01% 886
2021
Q1 		$343K Sell
8,195
-100
-1% -$4.64K ﹤0.01% 931
2020
Q4 		$386K Hold
8,295
– – ﹤0.01% 900
2020
Q3 		$353K Sell
8,295
-31,762
-79% -$1.39M ﹤0.01% 858
2020
Q2 		$1.92M Hold
40,057
– – 0.03% 509
2020
Q1 		$1.84M Hold
40,057
– – 0.03% 447
2019
Q4 		$2.4M Sell
40,057
-745
-2% -$44.4K 0.02% 532
2019
Q3 		$2.31M Hold
40,802
– – 0.03% 522
2019
Q2 		$2.27M Sell
40,802
-1,024
-2% -$53.4K 0.02% 540
2019
Q1 		$2.11M Hold
41,826
– – 0.02% 587
2018
Q4 		$1.69M Hold
41,826
– – 0.02% 612
2018
Q3 		$2.9M Hold
41,826
– – 0.03% 487
2018
Q2 		$3.17M Hold
41,826
– – 0.03% 451
2018
Q1 		$2.2M Sell
41,826
-2,998
-7% -$174K 0.02% 547
2017
Q4 		$2.39M Sell
44,824
-409
-0.9% -$22.8K 0.02% 544
2017
Q3 		$2.7M Sell
45,233
-1,467
-3% -$88.7K 0.02% 508
2017
Q2 		$3.68M Hold
46,700
– – 0.03% 409
2017
Q1 		$3.87M Sell
46,700
-2,183
-4% -$162K 0.03% 381
2016
Q4 		$3.88M Sell
48,883
-11,215
-19% -$815K 0.03% 421
2016
Q3 		$4.21M Sell
60,098
-16,200
-21% -$898K 0.03% 428
2016
Q2 		$2.96M Hold
76,298
– – 0.03% 545
2016
Q1 		$3.09M Hold
76,298
– – 0.03% 533
2015
Q4 		$6.76M Buy
76,298
+19,201
+34% +$1.52M 0.07% 289
2015
Q3 		$4.23M Hold
57,097
– – 0.04% 415
2015
Q2 		$4.62M Buy
+57,097
New +$3.72M 0.06% 409

Other funds holding EGRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SGCIA
Smith Graham & Co Investment Advisors Houston, Texas $868M AUM 24.69% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

QS Investors's EGRX Position: Q2 2021 in Review

QS Investors held its Eagle Pharmaceuticals, Inc. (EGRX) position steady in Q2 2021 at 8,195 shares worth $351K. The position accounts for ﹤0.01% of the portfolio, ranked #886.

QS Investors first reported a position in EGRX in Q2 2015 and has held it in 25 quarters since. The position peaked at $6.76M in Q4 2015. 146 funds tracked by Wall St. Rank hold EGRX as of Q2 2021.

  • QS Investors held 8,195 shares of Eagle Pharmaceuticals, Inc. worth $351K as of Q2 2021.
  • QS Investors left its Eagle Pharmaceuticals, Inc. share count unchanged in Q2 2021.
  • Eagle Pharmaceuticals, Inc. made up ﹤0.01% of QS Investors's portfolio in Q2 2021, its #886 holding.
  • QS Investors first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2015 and has held it in 25 quarters since.
  • QS Investors's Eagle Pharmaceuticals, Inc. position peaked at $6.76M in Q4 2015.
  • 146 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2021.

Based on QS Investors's 13F filing for Q2 2021, filed 13 Aug 2021.